New research from dariohealth expands evidence that personalized interventions impact health behaviors and improve user engagement

New york, june 29, 2021 /prnewswire/ -- dariohealth corp. (nasdaq: drio), a leader in the global digital therapeutics (dtx) market, presented new clinical research today at the american diabetes association (ada) 81st scientific sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care.     dario's latest research examines the impacts of the company's artificial intelligence (ai)-driven personalization engine on user engagement and clinical outcomes for close to 10,000 members.
DRIO Ratings Summary
DRIO Quant Ranking